Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma

International Journal of Cancer

Volumn 85, Issue 5, 2000, Pages 618-626

  Trefzer, Uwe ^a   Weingart, Guido ^a   Chen, Yingwen ^a   Herberth, Gunda ^a   Adrian, Karin ^a   Winter, Helmut ^a   Audring, Heike ^a   Guo, Yajun ^b   Sterry, Wolfram ^a   Walden, Peter ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b SIDNEY KIMMEL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HYBRID CELL; IMMUNOGENICITY; MALE; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; VACCINATION;

ADULT; AGED; B-LYMPHOCYTES; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE-FREE SURVIVAL; FEMALE; HLA-D ANTIGENS; HUMANS; HYBRID CELLS; MALE; MELANOMA; MIDDLE AGED; SAFETY; SKIN NEOPLASMS; T-LYMPHOCYTES; TIME FACTORS;

EID: 0033950319     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000301)85:5<618::AID-IJC4>3.0.CO;2-Z     Document Type: Article

References (22)

1. BANCHEREAU, J. and STEINMAN, R.M., Dendritic cells and the control of immunity. Nature (Lond.), 392, 245-252 (1998).
2. BENNETT, S.R., CARBONE, F.R., KARAMALIS, F., FLAVELL, R.A., MILLER, J.F. and HEATH, W.R., Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature (Lond.), 393, 478-480 (1998).
3. BORGES, E., WIESMUdie;LLER, K.-H., JUNG, G. and WALDEN, P., Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocyte responses: comparison of the costimulating support provided by helper T cells and lipoamino acid. J. immunol. Meth., 173, 253-263 (1994).
4. BOSSERHOFF, A.K., KAUFMANN, M., KALUZA, B., BARTKE, I., ZIRNGIBL, H., HEIN, R., STOLZ, W. and BUETTNER, B., Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res., 57, 3149-3153 (1997).
5. CHEN, L., ASHE, S., BRADY, W.A., HELLSTRÖM, I., HELLSTRÖM, K.E., LEDBETTER, J.A., MCGOWAN, P. and LINSLEY, P.S., Costimulation of antitumour immunity by the B7 counterreceptor for the T lymphocyte molecule CD28 and CTLA4. Cell 71, 1093-1102 (1992).
6. COLOMBO, M. P., MATTEI, S. and PARMIANI, G., Cytokine gene transfer in tumour cells as an approach to antitumour therapy. Int. J. Lab. Res., 21, 278-282 (1992).
7. GONG, J., CHEN, D., KASHIWABA, M. and KUFE, D., Induction of antitumor activity by immunisation with fusions of dendritic and carcinoma cells. Nature (Med.), 3, 558-561 (1997).
8. GUO, Y., WU, M., CHEN, H., WANG, X., LIU, G., LI, G., MA, J. and SY, M.S., Effective tumour vaccine generated by fusion of hepatoma cells with activated B cells. Science, 263, 518-520 (1994).
9. JURETIC, A., MALENICA, B., JURETIC, E., KLEIN, J. and NAGY, Z., Helper effects required during in vivo priming for a cytolytic response to the H-Y antigen in nonresponder mice. J. Immunol.,. 134, 1408-1410 (1985).
10. KERKMANN-TUCEK, A., BANAT, G.A., COCHLOVIUS, B. and ZÖLLER, M., Antigen loss variants of a murine renal cell carcinoma: implications for tumor vaccination. Int. J. Cancer, 77, 114-122 (1998).
11. KUGLER, A., SESEKE, F., THELEN, P., KALLERHOFF, M., MULLER, G.A., STUHLER, G., MULLER, C. and RINGERT, R.H., Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma. Brit. J. Urol., 82, 487-493 (1998).
12. MAAS, R.A., DULLENS, H.F.H. and DENOTTER, W., Interleukin-2 in cancer treatment-disappointing or (still) promising. Cancer Immunol. Immunther., 66, 141-148 (1993).
13. MITCHISON, N.A. and O'MALLEY, C., Three-cell-type clusters of T cells with antigen-presenting cells best explain the epitope linkage and noncognate requirements of the in-vivo cytolytic response. Europ. J. Immunol., 17, 1479-1483 (1987).
14. NESTLE, F.O., ALIJAGIC, S., GILLIET, M., SUN, Y., GRABBE, S., DUMMER, R., BURG, G. and SCHADENDORF, D., Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature (Med.), 4, 328-32 (1998).
15. PORGADOR, A. and GILBOA, E., Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. exp. Med. 182, 255-260 (1995).
16. RAES, G., VAN GINDERACHTER, J., LIU, Y.Q., BRYS, L., THIELEMANS, K., DE-BAETSELIER, P. and GELDHOF, A., Active antitumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model. Cancer Immunol. Immunother., 45, 257-265 (1998).
17. RIDGE, J.P., DI-ROSA, F. and MATZINGER, P., A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (Lond.), 393, 474-478 (1998).
18. SCHOENBERGER, S.P., TOES, R.E., VAN DER VOORT, E.I., OFFRINGA, R. and MELIEF, C.J., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (Lond.), 393, 480-483 (1998).
19. SIVANANDHAM, M., SHAW, P., BERNIK, S.F., PAOLETTI, E. and WALLACK, M.K., Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mite. Cancer Immunol. Immunother., 46, 261-267 (1998).
20. STAVELEY-O'CARROLL, K., SUTOMAYOR, E., MONTGOMERY, J., BORRELLO, I., HWANG, L., FEIN, S., PARDOLL, D. and LEVITSKY, H., Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Nat. Acad. Sci. (Wash.), 95, 1178-1183 (1998).
21. STUHLER, G. and WALDEN, P., Collaboration of helper and cytotoxic T lymphocytes. Europ. J. Immunol., 23, 2279-2286 (1993).
22. STUHLER, G. and WALDEN, P., Recruitment of helper T-cells for induction of tumour rejection by cytolytic T lymphocytes. Cancer Immunol. Immunother., 39, 342-345 (1994).